GlassScriptPhysician profile
James W Falconer
NPI 1295704641
$3,612.83
in general payments reported to CMS, 2019-2025
38 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $199 · 2021: $354 · 2022: $624 · 2023: $337 · 2024: $504 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $379.01 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $353.74 | 2019-2024 | Farxiga, Airsupra |
| Pfizer INC. | $304.23 | 2019-2025 | |
| Leo Pharma INC. | $291.39 | 2022-2025 | Adbry, Anzupgo |
| Glaxosmithkline, LLC. | $267.33 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $266.29 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.87 | 2019-2024 | Ofev, Spevigo |
| Lilly USA, LLC | $176.12 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $171.48 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $157.81 | 2019-2022 | |
| Abbvie INC. | $124.89 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $89.44 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $77.15 | 2021-2025 | Libtayo |
| Seqirus USA INC | $75.00 | 2019-2025 | Fluad, Flucelvax |
| Sunovion Pharmaceuticals INC. | $70.80 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $64.32 | 2019-2020 | |
| Sanofi Pasteur INC. | $53.05 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $36.15 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.97 | 2019-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $33.18 | 2023-2024 | Rexulti |
| Grifols USA, LLC | $32.28 | 2020 | |
| Mallinckrodt Hospital Products INC. | $32.14 | 2022 | |
| Insmed, INC. | $27.85 | 2019 | |
| Incyte Corporation | $23.24 | 2022 | |
| Sumitomo Pharma America, INC. | $22.92 | 2023 | Gemtesa |
| Almatica Pharma LLC | $19.89 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.83 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $19.01 | 2025 | |
| Organogenesis INC. | $17.95 | 2024 | Affinity |
| Amarin Pharma, INC. | $15.89 | 2019 | |
| Abbott Laboratories | $14.39 | 2021 | |
| Inari Medical, INC. | $13.28 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $12.65 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.13 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.68 | 2021 | |
| Valeritas, INC. | $10.86 | 2019 | |
| Inogen, INC. | $8.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Falconer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.